GAINESVILLE, Fla., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that the February 2011 issue of WOUNDS, the leading peer-reviewed journal in the wound care field, will feature an article authored by Quick-Med's Albina Mikhaylova, PhD. The article profiles the safety and antimicrobial efficacy of cutting edge antimicrobial dressings employing Quick-Med's patented NIMBUS technology and marketed by Derma Sciences, Inc. (Nasdaq:DSCI) under its BIOGUARD® trademark. Other Quick-Med authors include Bernd Liesenfeld, PhD, David Moore, BS, William Toreki, PhD, and Jill Vella, BS. Contributing authors from the University of Florida include professors Gregory Schultz, PhD, and Christopher Batich, PhD. Both Dr. Schultz and Dr. Batich are co-inventors of NIMBUS with Quick-Med.
The paper presents a preclinical evaluation of antimicrobial efficacy and biocompatibility of bacterial barrier dressings incorporating Quick-Med's proprietary NIMBUS technology. It notes that most bacterial barrier dressings in common usage today contain biocides that are released from the dressings and can be toxic to wound cells. The authors present the antimicrobial barrier properties of the novel BIOGUARD dressings and discuss how the underlying NIMBUS technology overcomes the significant limitations of antimicrobial technology currently used in wound dressings.
"The research confirms that BIOGUARD dressings safely demonstrate high performance against common wound pathogens without impeding healing", said Jerry Olderman, Vice President of Research and Development of Quick-Med Technologies. "The use of BIOGUARD dressings represents a new and significant way to augment the healing process because, as demonstrated in the study, while the active agent doesn't migrate into the wound it diminishes the bacterial load in the wound environment."
NIMBUS is the first non-leaching antimicrobial available in a bandage. It received U.S. Food and Drug Administration clearance in 2009. The bandages serve as a barrier to infection and kill germs such as MRSA and VRE. The antimicrobial does not leach into the wound to interfere with tissue healing. The NIMBUS active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates. By design, NIMBUS poses no risk of bacteria developing resistance.
The Company believes that being the only non-leaching antimicrobial bandage is an important distinction; silver and other antimicrobial dressings cost more and rely on the release of chemicals to the wound bed that can impede the wound healing process. NIMBUS technology is protected by nine U.S. patents and patents pending and 24 foreign counterparts.
WOUNDS is the most widely read, peer-reviewed journal focusing on wound care and wound research. The information disseminated to its readers includes valuable research and commentaries on tissue repair and regeneration, biology, and biochemistry of wound healing, and clinical management of wounds of various etiologies. It is the only wound care journal dedicated to the physician market. For more information, see: www.woundsresearch.com.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh™ technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.
|The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260|
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark and Stay Fresh™ and NimbuDerm™ are trademarks of Quick-Med Technologies, Inc. BIOGUARD® is a registered trademark of Derma Sciences, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies, Inc. J. Ladd Greeno, CEO (888) 835.2211 Ext 102 email@example.com Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 firstname.lastname@example.org
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here